ストックスクリーナーアプリを入手
0.7414
4.37%
-0.0339
プレマーケット:
.71
-0.0314
-4.24%
前日終値:
$0.7753
開ける：
$0.796
24時間の取引高:
106.72K
Relative Volume:
0.30
時価総額：
$9.18M
収益：
$285.80K
当期純損益:
$-12.60M
株価収益率:
-0.3755
EPS:
-1.9743
ネットキャッシュフロー:
$-13.44M
1週間 パフォーマンス:
-16.94%
1か月 パフォーマンス:
-12.07%
6か月 パフォーマンス:
-30.06%
1年 パフォーマンス:
-59.04%
1日の値動き範囲:
$0.73
$0.805
1週間の範囲:
$0.7101
$0.8999
52週間の値動き範囲:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
名前
Aprea Therapeutics Inc
セクター
電話
215-948-4119
住所
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.7414 | 9.60M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-06-22 | 開始されました | H.C. Wainwright | Neutral |
| 2020-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2019-10-28 | 開始されました | JP Morgan | Neutral |
| 2019-10-28 | 開始されました | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aprea Therapeutics Inc (APRE) 最新ニュース
Aprea Expands Cancer Trial After Early Tumor Responses - MyChesCo
Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers - BriefGlance
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2 - Moomoo
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - The Manila Times
Cancer trial drug APR-1051 posts partial responses at ASCO 2026 - Stock Titan
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - The Legal Advocate
Aprea Therapeutics (APRE) Edges Higher Amid Low Volume TradingATR Stop - The Legal Advocate
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN
Aprea Expands Cancer Trial After $30 Million Financing - MyChesCo
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know - sharewise.com
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com
[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan
Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks
Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo
Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo
Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart
Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress - TipRanks
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher - ChartMill
Aprea Therapeutics (NASDAQ: APRE) trims Q1 loss and raises over $34M to extend cash runway - Stock Titan
APREA THERAPEUTICS ($APRE) Releases Q1 2026 Earnings - Quiver Quantitative
Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary - TradingView
Aprea Therapeutics Reports Q1 2026 Results: $30M Financing Boosts APR-1051 Clinical Progress and Extends Cash Runway to 2028 - Minichart
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 Trial - Quiver Quantitative
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall - TradingView
8-K: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
Aprea (NASDAQ: APRE) extends cash runway and reports Q1 2026 results - Stock Titan
Early tumor responses and $30M cash boost for Aprea cancer drug - Stock Titan
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech - Barchart.com
TradingKey - TradingKey
APRE (Aprea) beats Q4 earnings by 20%, but shares fall 2.3% amid growth concerns.Earnings Growth Forecast - newsline.com
APRE (Aprea) Q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%.Put/Call Ratio - Newser
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target - marketscreener.com
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com Nigeria
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential By Investing.com - Investing.com South Africa
Aprea Therapeutics Inc (APRE) 財務データ
収益
当期純利益
現金流量
EPS
Aprea Therapeutics Inc (APRE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Jan 30 '26 |
Buy |
0.89 |
5,700 |
5,073 |
33,433 |
| Duey Marc | Director |
Dec 10 '25 |
Buy |
1.17 |
21,459 |
25,000 |
256,155 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
1.13%
3.22%
大文字化:
|
ボリューム (24 時間):